Monday, March 11, 2019
The Clean Facility of the Future documentary explores issues surrounding establishment and maintenance of clean facilities for biopharmaceutical reserach through discussions with thought leaders. In this round table series, we ask these thought leaders to expand on topics presented in the documentary. In this fifth roundtable discussion, key stakeholders were asked:
In the near future do you see pharmaceutical companies moving away from large cleanrooms to processing sterile products in isolators, gloveboxes or RABS? If so, why?
Check back to our first roundtable to read about must-have technologies for meeting microbial monitoring requirements, our second roundtable for a discussion on first steps a pharmaceutical company can take to upgrade microbial monitoring. Next up, our third roundtable features a discussion on whether pharmaceutical companies are likely to implement the same strict mircobial monitoring strategies used for sterile products on other types of products and finally our fourth roundtable discusses recommended practices a pharmaceutical company should put in place to collect, store, and analyze microbial monitoring data.